ACI Formulations PLC

ACI Formulations maintains a debt-to-equity ratio of 1.1, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.24, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of £192.8 million supports operational flexibility, though capital expenditures of £130.8 million in the latest period indicate ongoing investment in infrastructure. Profitability metrics show a return on equity of 10.39% and a return on assets of 4.32%, both below the industry median for Agricultural Chemicals. This suggests ACI Formulations is underperforming relative to its peers in asset utilization and shareholder returns. Gross profit of £1.67 billion and operating income of £780.4 million reflect a healthy margin structure, but net income of £370.8 million is constrained by interest and tax expenses. The company's revenue is concentrated in a single business segment focused on crop protection products, with no disclosed geographic diversification. This lack of segmentation increases exposure to regional demand shifts and regulatory changes in the agricultural sector. No material geographic breakdown is provided in the latest financials, limiting visibility into regional performance. Outlook data indicates a projected revenue increase of 8.2% in the current fiscal year and 5.1% in the following year, driven by new product launches and market expansion in key agricultural regions. However, the company's capital expenditures are expected to remain elevated, which may pressure near-term free cash flow. Risk factors include a negative net cash position after subtracting total debt, which could limit financial flexibility. The company's liquidity risk is moderate, but its debt load of £3.93 billion relative to equity of £3.57 billion raises concerns about leverage. Dilution risk is assessed as low, with no recent share issuance and no material dilution sources identified in the latest filings. Recent events include the filing of a 2023 annual report, which disclosed ongoing R&D investments in bio-based crop protection solutions. No material earnings call transcripts or regulatory actions were reported in the latest period.